Survey of 165 SLE patients, 127 on HCQ. 8 patients with suspected COVID-19 and 4 confirmed cases. No mortality, one ICU case. 7 patients had no symptoms despite contact with a COVID-19 patient.
This study is excluded in the after exclusion results of meta
analysis:
not fully adjusting for the different baseline risk of systemic autoimmune patients.
|
risk of case, 49.6% higher, RR 1.50, p = 0.59, treatment 10 of 127 (7.9%), control 2 of 38 (5.3%).
|
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Cassione et al., 12 May 2020, retrospective, Italy, peer-reviewed, survey, median age 52.5, 6 authors.
COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine
Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Professor Carlomaurizio Montecucco, Lorenzo Cavagna
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217717
Handling editor Josef S Smolen Acknowledgements The authors wish to thank Dr Luciano Perotti from the ICU department of our Hospital for his invaluable contribution to the good outcome of the admitted SLE patient.
References
Mathian, Mahevas, Rohmer, Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217566Monti, Balduzzi, Delvino, Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis,
doi:10.1136/annrheumdis-2020-217424
